Do you want to read an article? Please log in or register.
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report
Lung Cancer
Related content
RECOMMENDED
Lung Cancer
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Oncol
Scherpereel A, Baas P, Nowak AK, Tsao AS, Fujimoto N, Peters S, Mansfield AS, Popat S, Bautista Aragon Y, Talbot T, Grossi F, Kowalski D, Kaplan MA, Cardona AF, Soomro R, Hu N, Lee A, Ip V, Hung YH, Zalcman G
doi: 10.1200/JCO-25-01328
Lung Cancer
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
Lancet Oncol
Zhong H, Wang J, Yang R, Luo Y, Zuo W, Zhang W, Xie C, Li Q, Liu Q, Xu X, Wang Q, Yu Y, Chen Y, Yi T, Min X, Shi J, Yang J, Sun H, Chen H, Shi H, Gao J, Shi J, Zhang B, Chu T, Li K, Han B, CAMPASS Investigators
doi: 10.1016/S1470-2045(26)00049-5
Lung Cancer
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial
Lancet Respir Med
Wang L, Hao X, Hao Y, Hu Y, Chen C, Chen B, Huang Y, Zang A, Wang Y, Chen Z, Zhuang W, Shi J, Ren X, Nie L, Yu G, Luo F, Mao Y, Wang X, Li B, Bai Y, Shi J, Ni H, Yu H, Li J, Wang Q, Zhu J, Shi Y, ASTRUM-002 Study Group
doi: 10.1016/S2213-2600(25)00263-2
Lung Cancer
Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO
JTO Clin Res Rep
Falchero L, Amrane K, Godbert B, Leterre B, Madelaine J, Fournel P, Mascaux C, Raimbourg J, Schneider S, Swalduz A, Veillon R, Langlais A, Missy P, Morin F, Westeel V, Girard N
doi: 10.1016/j.jtocrr.2026.100964
RECOMMENDED
Lung Cancer
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Kinehara Y, Matsumoto K, Shiroyama T, Komuta K, Tamiya M, Nishino K, Tamiya A, Kuge T, Uchida J, Suzuki H, Yamamoto S, Tobita S, Niki T, Tetsumoto S, Morimura O, Osa A, Minami T, Nagatomo I, Takeda Y, Kijima T, Kumanogoh A
doi: 10.1016/j.lungcan.2026.109336
Lung Cancer
Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial
Lung Cancer
Isla D, Zugazagoitia J, Arriola E, García-Campelo R, Martí Blanco C, Diz-Taín MP, López-Brea M, Moreno-Vega AL, León-Mateos L, Oramás J, Gutiérrez-Calderón V, Majem M, Sánchez-Hernández A, Aguado C, Alvarez-Cabellos R, Massutí B, Moreno A, Fírvida-Pérez JL, Valdivia J, González-Cordero M, Zafra-Poves M, Dómine M, Garcia-Navalon FJ, Villanueva N, Provencio M, Juan-Vidal O, Rivas-Corredor C, Olmedo García ME, Palmero R, López-Castro R, Carcereny E, Lechuga JL, Domínguez M, Callejo Á, Paz-Ares L
doi: 10.1016/j.lungcan.2025.108763
RECOMMENDED
Pneumonia
The Long-term Pneumonia Mortality Index. An International Multicenter Derivation and Validation Study for Patients with Community-Acquired Pneumonia
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Am J Respir Crit Care Med
Méndez R, González-Jiménez P, Latorre A, Piqueras M, Mengot N, Hervás D, Knox D, Carr J, Barten-Neiner G, Rohde G, Pletz MW, Rupp J, Witzenrath M, Dean NC, Menéndez R
doi: 10.1093/ajrccm/aamag060
RECOMMENDED
Lung Cancer
Impact of First-Line Maintenance Immunotherapy With or Without Pemetrexed for Non-Squamous Advanced/Metastatic Non-Small Cell Lung Cancer Lacking Targetable Mutations: A Real-World Analysis in England
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
Clin Lung Cancer
Gomes F, Gilding N, Tan V, Christoforou K, Rule J, Aziez A, Januszewski A, Minchom A
doi: 10.1016/j.cllc.2025.12.007
RECOMMENDED
Lung Cancer
Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
ESMO Open
Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV
doi: 10.1016/j.esmoop.2025.106031